Patricia M Scott

Patricia M Scott is an active Assistant Professor in the Department of Biomedical Sciences at the University of Minnesota, focusing on the intersection of cystic fibrosis and gastrointestinal oncology. Her work examines how CFTR (cystic fibrosis transmembrane conductance regulator) gene dysfunction drives colorectal cancer development through microbiome alterations and molecular pathways, with significant contributions to understanding pro-oncogenic microbial interactions in CF patients.

Research interests include colorectal cancer pathogenesis, CFTR-related molecular mechanisms, gut microbiome dysbiosis in oncogenesis, and the role of specific bacterial pathogens (e.g., Fusobacterium nucleatum, pks+ E. coli). She investigates how CFTR deficiency creates a pro-tumor intestinal environment, explores BRAF V600E mutation impacts, and studies therapeutic modulators. Her fingerprint analysis highlights expertise in colon biology, KCNQ1 channels, tumor suppressor genes, and carcinogenesis within gastrointestinal cancers.

Recent publications (2019-2025) reveal consistent emphasis on CFTR-cancer links, spanning meta-analyses of mortality risks, reviews of molecular pathways, and mechanistic studies of bacterial oncogenesis. The work trends toward microbial drivers of cancer progression in CF patients, with increasing focus on clinical implications and therapeutic interventions.

Scientific awards and honors:

• No specific awards, fellowships, or medals were documented in the provided text.

Grant leadership and advising:

• Principal Investigator on 18 projects including Cystic Fibrosis Foundation grants (2025-2028) and Boomer Esiason Foundation funding (2025-2026)
• Active projects examine pro-oncogenic microbes, genotoxic E. coli, and lactic acid bacteria in CFTR-deficient colon epithelium
• Collaborates with clinical researchers (Khoruts, Hunter) and institutions like the Whiteside Institute for Clinical Research
• No student advising information was disclosed in the scraped data

She operates within interdisciplinary teams at the University of Minnesota, leveraging clinical research infrastructure to study CF-associated cancer mechanisms through microbiome-genome interactions, with ongoing work targeting future therapeutic strategies for high-risk CF populations.